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Arterial stiffness indexes and serum cytokine levels in seronegative
spondyloarthritis: relationships between stiffness markers and metabolic
and immunoinﬂammatory variables
A Tuttolomondo1, R Pecoraro1, C Buttà1, D Di Raimondo1, A Ferrante2, V Della Corte1, F Ciccia2, C Bellia3, A Giardina2,
A Raffa2, M Ciaccio3, A Pinto1
1Internal Medicine and Cardioangiology Unit, Biomedical Department of Internal Medicine and Specialties, 2Rheumatology Unit,
Biomedical Department of lnternal Medicine and Specialties, and 3Section of Clinical Biochemistry and Molecular Clinical Medicine,
Department of Medical and Forensic Biopathology and Biotechnology, University of Palermo, Italy
Objective: The aim of this study was to investigate the relationship between immunoinﬂammatory markers and indexes
of arterial stiffness in patients with seronegative spondyloarthritis (SpA).
Method: We enrolled consecutive patients with inﬂammatory seronegative SpA referred to a rheumatology outpatient
clinic. Control subjects were patients admitted in the same period for any cause other than chronic inﬂammatory disease
or acute cardiovascular and cerebrovascular events. Carotid-femoral pulse wave velocity (PWV) was measured and the
aortic pressure waveform was used to calculate the augmentation index (Aix). We also evaluated plasma levels of C-
reactive protein (CRP), interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and interleukin (IL)-6 as markers of
immunoinﬂammatory activation.
Results: This study enrolled 53 patients with SpA and 55 control subjects. After adjustment for blood glucose,
cholesterol, and triglyceride levels, and systolic (SBP) and diastolic blood pressure (DBP), patients with seronegative
SpA showed higher mean PWV and Aix compared to controls. Moreover, in patients with seronegative SpA, we
observed higher mean plasma levels of IL-6, IL-1β, and TNF-α in subjects with mean PWV > 8 m/s in comparison with
those with PWV < 8 m/s. Multivariate analysis revealed a signiﬁcant association between PWV > 8 m/s and male
gender, age, diabetes, hypertension, low density lipoprotein cholesterol (LDL-C) > 120 mg/dL, total cholesterol (TC) >
200 mg/dL, coronary artery disease (CAD), microalbuminuria, carotid plaque, and plasma levels of IL-6, IL-1β, and
TNF-α.
Conclusions: These ﬁndings emphasize the role of inﬂammatory variables and metabolic factors in indexes of high
arterial stiffness. Thus, an inﬂammatory-metabolic background may inﬂuence the pathogenesis of increased arterial
stiffness in seronegative inﬂammatory arthritis.
Seronegative spondyloarthritis (or spondylarthropathy,
SpA) comprises a family of inﬂammatory rheumatic
diseases involving the axial skeleton and having a nega-
tive serostatus. Entities included in the spondylarthropa-
thies are ankylosing spondylitis (AS), reactive arthritis,
psoriatic arthritis, undifferentiated SpA, and irritable
bowel disease (IBD). Cytokines are thought to play a
vital role in the immune dysregulation of SpA. Despite
their importance, cytokine proﬁles in SpA, either in
serum or within inﬂammatory cells, are largely
unknown. Aortic stiffness, wave-reﬂection intensity,
and endothelial function are independent predictors of
cardiovascular risk in various patient groups (1–4) and
may also directly accelerate the atherosclerotic process
(5). Some studies have reported an association between
SpA and cardiovascular risk (6, 7). Few studies have
examined the role of arterial stiffness and immuno-
inﬂammatory variables in patients with seronegative
SpA (8–10). On this basis, the aim of our study was to
investigate the relationship between immunoinﬂamma-
tory markers and arterial stiffness in patients with ser-
onegative SpA.
Method
We enrolled all consecutive patients with inﬂammatory
SpA referred to the rheumatology outpatient clinic of our
Biomedical Department of Internal Medicine and Spe-
cialties at the University of Palermo from September
2012 to December 2013.
Control subjects were patients admitted, in the same
period, to our Internal Medicine Department, for any
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cause other than chronic inﬂammatory disease or acute
cardiovascular and cerebrovascular events. To match
patients with inﬂammatory SpA and controls for cardio-
vascular risk and previous cardiovascular morbidity,
subjects were included among possible controls if they
had cardiovascular risk factors or previous cardiovascu-
lar or cerebrovascular events. Controls were excluded if
they had one of the following exclusion criteria: rheu-
matological disorders, chronic inﬂammatory disease,
acute systemic infections, recent venous thrombosis,
recent acute myocardial infarction (AMI) (within
3 months), or recent cerebrovascular event [transient
ischaemic attack (TIA) or stroke within 6 months]; all
these conditions may inﬂuence inﬂammatory cytokine
and cell levels.
Cardiovascular risk factors were evaluated for both
cases and controls on the basis of the following cri-
teria. Hypercholesterolaemia was deﬁned as the pre-
sence of total cholesterol (TC) blood levels ≥ 200 mg/
dL. Hypertension was deﬁned as present if subjects
had been previously diagnosed according to the World
Health Organization/International Society of Hyperten-
sion guidelines (11) and were routinely receiving anti-
hypertensive therapy. Patients were deﬁned as type 2
diabetics if they had known diabetes treated by diet,
oral hypoglycaemic drugs, or insulin. Previous coron-
ary artery disease (CAD) was determined on the basis
of a history of physician-diagnosed angina, MI, or any
previous revascularization procedure assessed by a
questionnaire. Previous cerebrovascular disease (TIA/
ischaemic stroke) was assessed by history, speciﬁc
neurological examination performed by specialists,
and hospital or radiological (brain computer tomogra-
phy or brain magnetic resonance imaging) records of
deﬁnite previous stroke. Subjects were classiﬁed as
having previous peripheral artery disease (PAD)
when they had a history of ankle-brachial index
(ABI) < 0.9 and/or intermittent claudication or critical
limb ischaemia, or when they had undergone a per-
ipheral arterial bypass or amputation.
The study protocol was approved by the local ethics
committee and all participants gave written informed
consent. Every subject with inﬂammatory SpA was
matched for age (±3 years), sex, and cardiovascular
risk factor prevalence with one control subject.
Pulse wave velocity (PWV) measurement
Carotid-femoral PWV was measured in the supine position
using an automatic device (SphygmoCor version 7.1). Dis-
tance was measured in millimetres on the skin surface,
subtracting the distance of the carotid artery to the sternal
notch from the distance measured between the sternal notch
and the peripheral artery of choice. Pulse wave analysis
(PWA) was performed at each arterial site in sequence and
the time difference was determined by identifying the foot of
the pulse waveform in relation to the QRS complex on a
simultaneous three-lead electrocardiogram (ECG).
PWV was calculated as the distance travelled by the
arterial pulse wave (in metres) divided by the time delay
between the two arterial points (in seconds), thus expressed
as m/s. Applanation tonometry was used to record the
radial artery pressure waveform continuously, and mean
values of ≥ 2 screens of pulse waves of good quality were
used for analysis. The aortic pressure waveform was used
to calculate the augmentation index (Aix), as the difference
in height between the ﬁrst and second systolic peaks
expressed as a percentage of pulse pressure.
Laboratory evaluation
Blood samples were obtained at rest in the supine posi-
tion. We evaluated plasma levels of C-reactive protein
(CRP), interleukin (IL)-1β, tumour necrosis factor
(TNF)-α, and IL-6 as markers of immunoinﬂammatory
activation. IL-1β, TNF-β, and IL-6 were measured using a
sandwich enzyme-linked immunosorbent assay (Quanti-
kine, R&D Systems, VWF ELISA kitdurian, Instrumenta-
tion Laboratory, Milan, Italy). The minimum detectable
concentrations for the diagnostic tests are: 1.6 pg/mL for
TNF-α, < 1 pg/mL for IL-1β, and < 0.70 pg/mL for IL-6.
Intra- and interassay coefﬁcients of variation were,
respectively, 4.2% and 4.6% for TNF-α, 3.3% and 4.2%
for IL-1β, and 1.6% and 3.3% for IL-6.
Statistical analysis
The results are expressed as mean ± sd for continuous
variables and percentages for categorical data, with
p ≥ 0.05 considered signiﬁcant.
All data were analysed using the SAS 9.1 statistical
program. Clinical characteristics were compared among
the four groups using a one-way analysis of variance
(ANOVA). Pearson’s correlation coefﬁcients were calcu-
lated to evaluate the relationship between arterial stiffness
indexes and immunoinﬂammatory (plasma cytokine
levels) and metabolic variables. Signiﬁcance was deﬁned
at the 0.05 conﬁdence level. Analysis of normality was
performed with the Shapiro–Wilk W test. Non-normally
distributed data were logarithmically (log 10) transformed
before analysis. The relationships between immunoinﬂam-
matory markers, PWV, Aix, and other parameters were
analysed using non-parametric methods (Spearman p cor-
relations) after correction for age and gender.
Logistical regression analysis was conducted with data
presented as odds ratios (ORs) with 95% conﬁdence inter-
vals (CIs). Initial univariate analyses identiﬁed demo-
graphic and clinical variables that independently
predicted arterial stiffness as PWV > 8 m/s. Signiﬁcant
variables were entered into subsequent multivariate logis-
tical regression analysis with the variables included in the
models using forward stepwise selection, with a
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probability value of 0.05 required for entry into the model.
A probability value ≤ 0.05 was considered signiﬁcant.
Results
We enrolled 53 patients with SpA and 55 control sub-
jects without SpA matched for cardiovascular risk and
previous cardiovascular morbidity. Demographic and
clinical variables are listed in Table 1. Among the
patients with SpA, 18 (33.96%) had AS and 35
(66.04%) had psoriatic arthritis.
After adjustment for blood glucose, cholesterol, and
triglyceride levels, systolic (SBP) and diastolic blood
pressure (DBP), patients with SpA showed a higher
mean PWV (9.98 ± 2.9 vs. 6.79 ± 3.1 m/s, p < 0.05)
and Aix (94.3 ± 3.5% vs. 88 ± 4.6%) compared to
control subjects. SpA patients showed higher mean
plasma levels of IL-6, IL-1β, and TNF-α in comparison
with controls.
In particular, in SpA patients we observed higher
mean plasma levels of IL-6 (8.21 vs. 6.14 pg/mL, p =
0.011), IL-1β (4.11 vs. 2.14 pg/mL, p = 0.032), and
TNF-α (31.11 vs. 10.74 pg/mL, p < 0.001) among
those with mean PWV > 8 m/s in comparison with
those with PWV < 8 m/s (Table 2).
In patients with SpA, we observed a signiﬁcant corre-
lation between PWV and SBP (R = 0.38, p = 0.040),
hypertension (R = 0.36, p < 0.05), blood glucose levels
(R = 0.31, p < 0.05), plasma low density lipoprotein
cholesterol (LDL-C) plasma (R = 0.30, p = 0.011),
plasma TC levels (R = 0.31, p = 0.010), CAD (R =
0.29, p = 0.022), microalbuminuria (R = 0.30, p < 0.05),
carotid plaque (R = 0.29, p = 0.030), left ventricular
Table 1. Demographic and clinical characteristics of patients with spondyloarthritis (SpA) and controls.
Patients with SpA Controls p-value
n 53 55 0.71
Males/Females 28/25 30/25 0.55
Age (years) 52.28 ± 4.2 54.28 ± 2.7 0.63
Type of SpA
Ankylosing spondylitis (AS) 18 (33.96)
Psoriatic arthritis 35 (66.04)
Duration of disease (years) 7 ± 2.5
SBP (mmHg) 142.06 ± 7.4 141.05 ± 4.4 0.33
DBP (mmHg) 90.88 ± 4.8 89.46 ± 3.6 0.25
HR (beats/min) 76.75 ± 9.2 78.25 ± 7.2 0.18
Medications
ACE inhibitors 2 (3.77) 3 (5.44) 0.31
ARBs 1 (1.88) 1 (1.86) 0.40
Methotrexate 7 (13.20) – 0.29
Cox-2 inhibitors 3 (5.66) – 0.77
Steroids 4 (7.54) –
Biologics 8 (15.09) –
ASA 3 (5.66) 4 (7.27)
Statins 5 (9.43) 2 (3.66)
Hypertension 8 (15.09) 7 (12.72) 0.81
Diabetes 5 (9.43) 6 (10.90) 0.55
Metabolic syndrome 3 (5.56 4 (7.27) 0.61
CAD 3 (5.56) 4 (7.27) 0.59
PWV (m/s) 9.98 ± 2.9 6.79 ± 3.1 < 0.05
Aix (%) 94.3 ± 3.5 88 ± 4.6 0.021
CHF 10 (18.86) 10 (18.80) 0.065
LVH 11 (20.14) 9 (16.36) 0.071
Carotid plaque 9 (16.98) 10 (18.18) 0.56
IL-6 (pg/mL) 7.18 (4.24–10.95) 2.22 (1.04–3.25) 0.001
TNF-α (pg/mL) 20.94 (6.71–42.70) 8.38 (6.78–8.55) < 0.001
IL-1β (pg/mL) 3.13 (1.08–5.01) 1.49 (1.01–2.76) 0.033
ABI 0.85 0.88 0.52
Glucose (mg/dL) 101 ± 2.3 99 ± 2.8 0.43
LDL-C (mg/dL) 112 ± 4.5 109 ± 5.5 0.55
TC (mg/dL) 214 ± 11.5 202 ± 9.4 0.77
Triglycerides (mg/dL) 159 ± 11.5 161 ± 8.7 0.89
SBP, Systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ACE, angiotensin-converting enzyme; ARB, angiotensin II
receptor blocker; ASA, acetylsalicylic acid (Aspirin); CAD, coronary artery disease; PWV, pulse wave velocity; Aix, augmentation
index; CHF, congestive heart failure; LVH, left ventricular hypertrophy, IL-6, interleukin-6; TNF-α, tumour necrosis factor α; IL-1β,
interleukin 1β; ABI, ankle brachial index; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol.
Values are given as mean ± sd, n (%), or median (IQR).
Ankle brachial index (ABI).
Statistically signiﬁcant variables are expressed in bold type.
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hypertrophy (LVH; R = 0.24, p = 0.039), IL-6 (R = 0.38,
p < 0.05), TNF-α (R = 0.44, p < 0.001), IL-1β (R = 0.39,
p < 0.05) (Table 3).
With regard to logistical regression analysis of demo-
graphic and clinical variables associated with PWV > 8
m/s in patients with SpA, at univariate analysis we
observed a signiﬁcant association with male gender,
age, diabetes, hypertension, atrial ﬁbrillation, blood glu-
cose levels > 150 mg/dL, LDL-C > 120 mg/dL, plasma
TC > 200 mg/dL, CAD, microalbuminuria, and carotid
plaque (Table 4).
At multivariate analysis, we observed a signiﬁcant
association between PWV > 8 m/s and male gender
(OR 1.45, 95% CI 0.98–2.77, p = 0.044), age (OR
3.09, 95% CI 2.21–4.01, p < 0.001), diabetes (OR
2.86, 95% CI 1.21–3.69, p = 0.032), hypertension (OR
3.01, 95% CI 2.01–4.01, p < 0.005), LDL-C levels >
120 mg/dL (OR 1.85, 95% CI 1.12–2.88, p = 0.038),
plasma TC levels > 200 mg/dL (OR 1.72, 95% CI
1.01–2.35, p = 0.041), CAD (OR 2.43, 95% CI
1.31–2.87, 1.31–2.87, p = 0.023), microalbuminuria
(OR 2.51, 95% CI 1.24–2.79, p = 0.020), carotid plaque
(OR 2.91, 95% CI 1.54–4.01, p = 0.027), IL-6 (OR 3.09,
95% CI 2.02–5.01, p = 0.009), IL-1β (OR 3.11, 95% CI
1.54–4.01, p < 0.05), and TNF-α (OR 3.99, 95% CI
3.17–5.33, p < 0.001) (see Table 4).
Discussion
Our study shows that subjects with SpA have higher
median serum levels of immunoinﬂammatory mar-
kers such as IL1-β, IL-6, and TNF-α in comparison
with controls. Several studies (12–14) have shown
that TNF-α levels are raised at baseline in patients
with SpA. Gratacos et al (15) showed that TNF-α and
IL-6 levels were raised in patients with AS compared
with patients with non-inﬂammatory back pain. No
signiﬁcant difference in interferon (IFN)-γ levels was
found. However, several trials no found increased
levels of other serum pro-inﬂammatory or anti-
inﬂammatory cytokines in SpA (12–15).
In our patients with SpA, we observed higher
median values of arterial stiffness markers such as
PWV and Aix in comparison with control subjects.
In general, arterial stiffness indexes represent a sub-
clinical marker of atherosclerosis. Hence it is possi-
ble to hypothesize that patients affected by SpA
could be prone to atherosclerosis.
Atherosclerosis and arthritis share several pathophy-
siological characteristics. Both conditions seem to be
provoked by initial cell injury (to endothelial cells in
atherosclerosis and to synovial cells in rheumatoid
arthritis) and a central role is played by macrophages,
T lymphocytes and connective tissue cells, accompanied
by the formation of an extracellular matrix (16). Thus, a
possible link between arthritis or spondyloarthritis and
arterial stiffness could be represented by immunoinﬂam-
matory activation.
Analogously, some data suggest that inﬂammation
may play a direct role in mediating arterial stiffness
(17). Reactive oxygen species (ROS) constitute
another category of compounds that exert effects on
Table 2. Immunoinﬂammatory variables in patients with spondyloarthritis (SpA) and in controls in relation to PWV values.
Patients with SpA (n = 53) Controls (n = 55)
PWV < 8 m/s PWV > 8 m/s p-value PWV < 8 m/s PWV > 8 m/s p-value
n (%) 15 (28.30) 38 (71.69) 39 (70.90) 16 (29.09)
IL-6 (pg/mL) 6.14 (4.84–7.95) 8.21 (6.24–10.95) 0.0011 2.11 (1.04–3.25) 2.34 (1.32–3.27) 0.77
IL-1β (pg/mL) 2.14 (1.08–3.77) 4.11 (2.24–5.01) 0.032 1.14 (1.01–2.47) 1.84 (1.21–2.76) 0.22
TNF-α (pg/mL) 10.74 (6.71–6.84) 31.11 (16.24–2.70) < 0.001 8.77 (6.78–8.65) 7.99 (5.04–8.55) 0.045
PWV, Pulse wave velocity; IL-6, interleukin-6; TNF-α, tumour necrosis factor alpha; IL-1β, interleukin 1β.
Values are given as median (IQR).
Statistically signiﬁcant variables are expressed in bold type.
Table 3. Correlations between PWV and clinical variables in
patients with spondyloarthritis (n = 53).
Variable R p-value
Age 0.41 0.85
SBP 0.38 0.04
DBP 0.36 0.52
Hypertension 0.36 < 0.05
Diabetes 0.38 < 0.05
Atrial ﬁbrillation 0.21 0.74
Glucose blood levels 0.31 < 0.05
LDL-C plasma levels 0.30 0.011
TC plasma levels 0.31 0.01
Triglyceride plasma levels 0.23 0.52
CAD 0.29 0.022
CHF 0.21 0.55
Microalbuminuria 0.30 < 0.05
Carotid plaque 0.29 0.03
LVH 0.24 0.039
IL-6 0.38 < 0.05
IL-1β 0.39 < 0.05
TNF-α 0.44 < 0.001
PWV, Pulse wave velocity; SBP, systolic blood pressure; DBP,
diastolic blood pressure; LDL-C, low density lipoprotein cho-
lesterol; TC, total cholesterol; CAD, coronary artery disease;
CHF, congestive heart failure; LVH, left ventricular hypertrophy;
IL-6, interleukin-6; IL-1β, interleukin 1β; TNF-α, tumour necrosis
factor α.
Statistically signiﬁcant variables are expressed in bold type.
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both cartilage and the vasculature. Free radical spe-
cies have been implicated in cartilage degeneration
and the pathogenesis of osteoarthritis, for example,
by causing chondrocyte lipid peroxidation, a reaction
that has been directly linked to collagen oxidation
and degradation. Similarly, oxidative stress has been
shown to promote vascular disease (18) and experi-
mental evidence has demonstrated that reducing oxi-
dative stress may reduce aortic stiffness (19).
Our ﬁndings also showed higher plasma cytokine
levels in patients with SpA and mean PWV > 8 m/s in
comparison with those with PWV < 8 m/s and this
ﬁnding could represent a further conﬁrmation of the
relationship between immunoinﬂammatory activation
and arterial stiffness.
Nevertheless, inﬂammation cannot be the only patho-
genetic background of arterial stiffness in subjects with
inﬂammatory arthropathies. In a recent study that
enrolled patients with AS after 24 weeks of anti-TNF-α
therapy, despite signiﬁcant improvements in patients
symptoms, clinical activity parameters, and CRP levels,
no signiﬁcant change was seen in arterial stiffness para-
meters (9). On this basis, other factors in addition to
inﬂammatory markers such as metabolic variables
(blood glucose, cholesterol, and triglyceride levels) or
endothelial damage variables such as ROS and nitric
oxide (NO) may play a role in the pathogenesis of
arterial stiffness in patients with inﬂammatory arthritis.
Our ﬁndings show, in addition to a signiﬁcant
correlation between arterial stiffness and markers of
immunoinﬂammatory variables such as plasma
cytokine values, a correlation between PWV and
clinical and metabolic variables such as hypertension,
blood glucose, plasma LDL-C and TC levels, CAD,
and microalbuminuria. Hence, metabolic variables
could also have a role in inﬂuencing arterial stiffness
indexes even in the clinical context of an inﬂamma-
tory disease (20–26).
Moreover, in our study we evaluated predictive vari-
ables of arterial stiffness in SpA. Our ﬁndings show that
age, diabetes, hypertension, LDL-C > 120 mg/dL,
plasma TC levels, CAD, microalbuminuria, carotid pla-
que and, in particular, plasma IL-6, IL-1β, and TNF-α
levels are signiﬁcant predictive variables of arterial stiff-
ness in SpA patients with PWV > 8 m/s.
The strengths of our study lie in the decision to
evaluate a control group of subject also matched for
cardiovascular risk factors and subclinical atherosclero-
sis prevalence; thus we have limited possible bias due to
the effects of atherosclerosis burden on inﬂammatory
markers.
Our study also has some limitations: the relatively
small sample size, the possible effects of clinical
disease activity on inﬂammatory markers, and our
assessment of vascular stiffening by PWV, which
reﬂects central and not peripheral arterial stiffness.
In conclusion, our ﬁndings emphasize the role of inﬂam-
matory variables and metabolic factors as determinants of
high arterial stiffness markers. Thus, an inﬂammatory-
metabolic background may inﬂuence the pathogenesis of
increased arterial stiffness in seronegative inﬂammatory
arthritis.
Table 4. Univariate and multivariate logistic regression analysis of demographic and clinical variables associated with PWV > 8 m/s
in patients with seronegative spondyloarthritis (SpA).
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Gender (male) 2.12 (1.23–4.78) 0.016 1.45 (0.98–2.77) 0.044
Age 3.34 (2.67–4.02) < 0.001 3.09 (2.21–4.01) < 0.001
Diabetes 3.09 (1.87–3.33) < 0.005 2.86 (1.21–3.69) 0.032
Hypertension 3.78 (2.76–4.98) < 0.001 3.01 (2.01–4.01) < 0.005
Atrial ﬁbrillation 1.67 (0.93–2.23) 0.039 0.92 (0.22–2.41) 0.44
Blood glucose > 150 mg/dL 1.66 (0.71–2.34) 0.023 0.67 (0.12–2.56) 0.57
Plasma LDL-C > 120 mg/dL 2.62 (1.44–3.00) 0.019 1.85 (1.12–2.88) 0.038
Plasma TC > 200 mg/dL 2.01 (1.11–2.78) 0.033 1.72 (1.01–2.35) 0.041
Plasma triglyceride > 200 mg/dL 0.99 (0.23–1.67) 0.77 0.88 (0.37–1.78) 0.79
CAD 2.66 (1.56–3.11) 0.011 2.43 (1.31–2.87) 0.023
CHF 0.89 (0.51–1.55) 0.67 0.81 (0.47–1.42) 0.59
Microalbuminuria 2.85 (1.37–3.09) < 0.005 2.51 (1.24–2.79) 0.020
Carotid plaque 3.23 (2.13–3.79 < 0.001 2.91 (1.54–4.01) 0.027
LVH 0.80 (0.11–1.54) 0.61 0.66 (0.33–1.69) 0.53
IL-6 3.71 (2.22–4.45) < 0.001 3.09 (2.02–5.01) 0.009
IL-1β 4.19 (3.01–5.67) < 0.001 3.11 (2.45–4.98) < 0.05
TNF-α 5.32 (3.99–6.01) < 0.001 3.99 (3.17–5.33) < 0.001
PWV, Pulse wave velocity; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; CAD, coronary artery disease; CHF,
congestive heart failure; LVH, left ventricular hypertrophy; IL-6, interleukin-6; IL-1β, interleukin 1β; TNF-α, tumour necrosis factor α;
OR, odds ratio; CI, conﬁdence interval.
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